Clinical trials: Binge-Eating Disorder
Binge-eating Disorder
Drug Use Study With VYVANSE® in Australia for Binge Eating Disorder
This study will check how and to whom Vyvanse is prescribed in Australia by retrospectively analyzing a prescription database with additional information provided by a physician survey.
- Trial name
- NCT04866043
- Where
- Australia
- Volunteers
- 150 people
- Sponsor
- Shire
Binge Eating Disorder
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A study to evaluate a drug (dasotraline) on the safety, effectiveness and how well the body tolerates it, in adults with moderate to severe binge eating disorder
- Trial name
- NCT03107026
- Testing
- dasotraline 4mg, dasotraline 6mg
- Where
- 50 sites in United States
- Volunteers
- 491 people
- Sponsor
- Sumitomo Pharma America, Inc.
Binge Eating
An Efficacy and Tolerability Study for Topiramate in Obese Patients With Binge Eating Disorder.
The purpose of this study is to evaluate the effectiveness and tolerability of topiramate compared to placebo in patients with binge eating disorder receiving Cognitive Behavior Therapy (CBT)
- Trial name
- NCT00307619
- Testing
- topiramate
- Volunteers
- 73 people
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Obesity, Binge-Eating Disorder
A Study of the Effectiveness and Safety of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity
The purpose of this study is to evaluate the safety and effectiveness of topiramate compared to placebo in reducing the number of binge days in patients with moderate to severe binge-eating disorder associated with obesity.
- Trial name
- NCT00210808
- Testing
- topiramate
- Volunteers
- 407 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Binge Eating, Obesity
Feasibility of a Digital Therapeutic for Adults With Binge Eating and Obesity
The primary objective of this study is to test the feasibility of a digital therapeutic to address comorbid binge eating and obesity in adults.
- Trial name
- NCT06454123
- Testing
- OTX-401
- Volunteers
- 30 people
- Sponsor
- Oui Therapeutics, Inc.
Binge Eating Disorder
Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder
To evaluate the efficacy of SPD489 compared to placebo in the treatment of moderate to severe binge eating disorder as measured by the number of binge days per week
- Trial name
- BED (NCT01291173)
- Testing
- lisdexamfetamine dimesylate (SPD489)
- Where
- 31 sites in United States
- Volunteers
- 271 people
- Sponsor
- Shire
Binge Eating, Binge-Eating Disorder
EXOMIND (BTL-995) for the Reduction of Binge-eating
The goal of this clinical trial is to evaluate if the treatment with the BTL-995-rTMS device is able to reduce binge eating in adults above the age of 22 years.
- Trial name
- NCT06894615
- Testing
- Treatment with BTL-995-rTMS
- Where
- Czechia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- BTL Industries Ltd.
Binge-Eating Disorder
Technology Assisted Treatment for Binge Eating Behavior
Binge-eating behavior is a central feature of eating disorders (e.g., binge-eating disorder, bulimia nervosa, anorexia nervosa-binge-eating/purging subtype) and is associated with higher rates of psychopathology, psychosocial…
- Trial name
- NCT05829941
- Testing
- Smartwatch app to deliver binge-eating CBT strategies, Reminder control condition
- Volunteers
- 30 people
- Sponsor
- HabitAware Inc.
Binge-Eating Disorder
Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder
Placebo-controlled study to evaluate the efficacy and safety of oral ACT-539313 in the treatment of adults with moderate to severe binge eating disorder
- Trial name
- NCT04753164
- Testing
- ACT-539313
- Where
- 30 sites in United States
- Volunteers
- 136 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.